An Observational Post-Authorization Safety Study (PASS) of Victrelis (Boceprevir) Among Chronic Hepatitis C Patients
Phase of Trial: Phase IV
Latest Information Update: 23 Sep 2016
At a glance
- Drugs Boceprevir (Primary) ; Peginterferon; Ribavirin; Telaprevir
- Indications Hepatitis C
- Focus Adverse reactions; Therapeutic Use
- Sponsors Merck & Co; Schering-Plough
- 30 Jun 2015 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record .
- 19 Jul 2014 Status changed from recruiting to active, no longer recruiting as reported by United Kingdom Clinical Research Network.
- 29 May 2014 Planned End Date changed from 1 Mar 2015 to 1 Jun 2015 as reported by ClinicalTrials.gov record.